WajeehaAbdulRazaqMD

Oncology • Oklahoma City, OK

Assistant Professor, Medicine, University of Oklahoma College of Medicine

Join to view full profile

Dr. Razaq is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Razaq's full profile

Already have an account?

Office
800 Ne 10th St
Oklahoma City, OK 73104
Phone+1 405-271-4022

Fax+1 405-271-4221

Education & Training

Icahn School of Medicine at Mount Sinai/St Luke’s-Roosevelt Hospital CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 2002 - 2005
King Edward Medical UniversityClass of 2000

Certifications & Licensure

OK State Medical License 2012 - 2026
KS State Medical License 2011 - 2012
NE State Medical License 2008 - 2012
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Ca...
Mariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, Matthew P Goetz, Priya Rastogi
Journal of Clinical Oncology. 2024-09-01
NRG-CC004 ancillary data study-exploring the effect of bupropion on sexual desire in female cancer survivors with and without vulvovaginal symptoms.
Jeanne Carter, Stephanie L Pugh, Noel Arring, Ramey D Littell, Seth J Page
The Journal of Sexual Medicine. 2024-08-01
Correction: annexin A5-DM1 protein-drug conjugate for the treatment of triple-negative breast cancer.
Alexis Woodward, Benjamin Southard, Sampurna Chakraborty, Aaron O Bailey, Gabriela N F Faria
Molecular Biomedicine. 2024-04-02

Press Mentions

Tumor Boards Enhance Outcomes at OU Health Stephenson Cancer CenterJuly 4th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member